High-Impact Movers for May 31st
Portfolio Pulse from Benzinga Newsdesk
Marker Therapeutics reports pre-clinical data of MT-601 in lymphoma cells, Adamas One acquires a minority stake in NexGenAI Solutions Group, and Trevena receives a milestone payment from Jiangsu Nhwa Pharmaceutical.
May 31, 2023 | 12:50 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Adamas One acquired a minority equity stake in artificial intelligence solutions provider NexGenAI Solutions Group.
Adamas One's acquisition of a minority stake in NexGenAI Solutions Group could be seen as a strategic move to expand its portfolio, potentially leading to a positive impact on JEWL's stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
Marker Therapeutics reported positive pre-clinical data for its MT-601 MultiTAA-Specific T Cell Product Candidate in lymphoma cells.
Positive pre-clinical data for MT-601 is likely to boost investor confidence in Marker Therapeutics, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Trevena announced the receipt of a milestone payment from its partner in China, Jiangsu Nhwa Pharmaceutical.
The milestone payment received by Trevena from Jiangsu Nhwa Pharmaceutical indicates progress in their partnership, which could positively impact TRVN's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 60
RELEVANCE 100